A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

Conditions

• Solid Tumor (Phase I)
• RAS Mutation
• CEACAM5

Interventions

• DRUG: Intravenous AN4035
• DRUG: Intravenous AN4035 followed by intravenous EGFR Inhibitor.

Sponsor

Adlai Nortye Biopharma Co., Ltd.